Mark Cuban

Mark Cuban × Chamath Palihapitiya × Jason Calacanis × David Sacks × David Friedberg

The AI bubble’s likely casualties are VCs, funds, and PE firms concentrated in peak-priced private rounds, while infrastructure spending depends on whether token economics and video demand justify today’s buildout.Enterprise implementation remains the bottleneck as agents drift and require forward-deployed talent, but falling build costs are opening bespoke software and IPO-funded acquisition strategies for smaller AI companies.

Erik Torenberg × Mark Cuban

Cuban’s clearest business thesis pairs transparent pricing and AI-native operators with broad employee equity, arguing that ESOP workers earn dramatically more and turn over less while small firms gain immediate productivity tools.He would replace opaque insurers and PBMs with patient shopping, catastrophic reinsurance, and government-guaranteed financing, while NBA media rights and second-apron constraints make subscription growth and patient team-building the next tests.

Mark Cuban × Tucker Carlson

Cost Plus Drugs exposes extreme pricing gaps by publishing drug costs, adding 15%, and charging $5 each for shipping and pharmacist review, with customers reporting $21 bills instead of $900-$2,000 quotes.PBM formularies control access for more than 180 million people and can block manufacturers from supplying Cost Plus, while the ACA subsidy cliff could raise premiums for 12.5 million people, making transparency, reform, and political execution key risks to monitor.